Impact of Parthanatos on the Increased Risk of Onset and Mortality in Male Patients With Pulmonary Hypertension

Abstract

There have been no studies as to whether parthanatos, a poly (adenosine diphosphate-ribose) polymerase-1 (PARP-1)-dependent and apoptosis-inducing factor (AIF)-mediated caspase-independent programmed cell death, is present in pulmonary hypertension (PH). Basic studies have, however, been conducted on several of the key molecules in parthanatos, such as PARP-1, AIF, and macrophage migration inhibitory factor (MIF). For this study, we collected blood samples from 88 incident male patients with PH and 50 healthy controls at the Shanghai Pulmonary Hospital. We measured the key factors of parthanatos (PARP-1, PAR, AIF, and MIF) by enzyme-linked immunosorbent assay and performed a logistic regression, Cox proportional hazards analysis, and Kaplan–Meier test to assess the prognostic value of the key molecules in diagnosing and predicting survival. The patients who ultimately died had a significantly poorer clinical status during the study than those who survived. The PARP-1, PAR, AIF, and MIF levels were significantly higher in the patients than in the controls (all p < .0001), and the PARP-1, PAR, and AIF levels were higher in the nonsurvivors than in the survivors (all p < .0001). PARP-1 and AIF levels served as independent predictors of disease onset and mortality in these patients (all p < .005). Patients with PARP-1 levels <11.24 ng/mL or AIF levels <1.459 pg/mL had significantly better survival than those with higher PARP-1 or AIF levels ( p < .0001). Circulating levels of PARP-1 and AIF were independent predictors for PH onset and mortality, which indicated that parthanatos might be associated with the pathogenesis of PH.

Cancer treatment-induced NAD+ depletion in premature senescence and late cardiovascular complications

“…However, excessive DNA damage leads to PARP1 overactivation, severe NAD + depletion, and cell death. PARP1-dependent DNA damage-induced programmed cell death pathway, namely “parthanatos”, has been implicated in heart diseases [ 131 ] . In cancer cells, such as breast and ovarian cancers, HR is less effective due to mutations in DNA repair genes, e.g., BRCA1, BRCA2.…”

Premature senescence and cardiovascular disease following cancer treatments: mechanistic insights

“…Anti-melanoma cancer treatments activate PARP1-NF-kb signaling, resulting in SASP ( 335 ). However, excessive DNA damage can lead to PARP1 overactivation, causing cell death known as “Parthanatos” ( 336 ). PARP inhibitors such as olaparib, INO-1001 (an isoindolinone-based PARP inhibitor), and veliparib are used to treat CVD, pulmonary arterial hypertension, and cardiac repolarization in cancer survivors.…”